Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment
BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease （PD）. Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased ri...
Saved in:
| Published in | Journal of geriatric cardiology : JGC Vol. 13; no. 1; pp. 75 - 80 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
China
Department of Cardiology, 0rdu University Medical School, 0rdu, Turkey%Department of Neurology, 0rdu University Medical School, 0rdu, Turkey%Department of Cardiology, Giresun University Medical School, Giresun, Turkey%Department of Cardiology, Siyami Ersek Research and Training Hospital,?stanbul, Turkey
2016
Science Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1671-5411 |
| DOI | 10.11909/j.issn.1671-5411.2016.01.003 |
Cover
| Abstract | BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease （PD）. Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.MethodsThe study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.ResultsAs an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels （15.1 ± 3.9 μmol/Lvs. 11.5 ± 3.2 μmol/L,P = 0.02）. Aortic distensibility was significantly lower in the patients with PD when compared to controls （4.8 ± 1.5 dyn/cm2vs. 6.2 ± 1.9 dyn/cm2,P = 0.016）. Additionally, the patients with PD had higher aortic strain and aortic stiffness index （13.4% ± 6.4%vs. 7.4% ± 3.6%,P 〈 0.001 and 7.3 ± 1.5vs. 4.9 ± 1.9,P〈 0.001 respectively）. Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine （r = 0.674,P 〈 0.001;r=-0.602,P 〈 0.001, respectively）.ConclusionsThe patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological me-chanism. |
|---|---|
| AbstractList | BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease （PD）. Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.MethodsThe study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.ResultsAs an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels （15.1 ± 3.9 μmol/Lvs. 11.5 ± 3.2 μmol/L,P = 0.02）. Aortic distensibility was significantly lower in the patients with PD when compared to controls （4.8 ± 1.5 dyn/cm2vs. 6.2 ± 1.9 dyn/cm2,P = 0.016）. Additionally, the patients with PD had higher aortic strain and aortic stiffness index （13.4% ± 6.4%vs. 7.4% ± 3.6%,P 〈 0.001 and 7.3 ± 1.5vs. 4.9 ± 1.9,P〈 0.001 respectively）. Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine （r = 0.674,P 〈 0.001;r=-0.602,P 〈 0.001, respectively）.ConclusionsThe patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological me-chanism. Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment. The study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls. As an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels (15.1 ± 3.9 µmol/L vs. 11.5 ± 3.2 µmol/L, P = 0.02). Aortic distensibility was significantly lower in the patients with PD when compared to controls (4.8 ± 1.5 dyn/cm(2) vs. 6.2 ± 1.9 dyn/cm(2), P = 0.016). Additionally, the patients with PD had higher aortic strain and aortic stiffness index (13.4% ± 6.4% vs. 7.4% ± 3.6%, P < 0.001 and 7.3 ± 1.5 vs. 4.9 ± 1.9, P < 0.001 respectively). Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine (r = 0.674, P < 0.001; r = -0.602, P < 0.001, respectively). The patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological mechanism. BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.MethodsThe study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.ResultsAs an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels (15.1 ± 3.9 μmol/Lvs. 11.5 ± 3.2 μmol/L,P = 0.02). Aortic distensibility was significantly lower in the patients with PD when compared to controls (4.8 ± 1.5 dyn/cm2vs. 6.2 ± 1.9 dyn/cm2,P = 0.016). Additionally, the patients with PD had higher aortic strain and aortic stiffness index (13.4% ± 6.4%vs. 7.4% ± 3.6%,P < 0.001 and 7.3 ± 1.5vs. 4.9 ± 1.9,P< 0.001 respectively). Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine (r = 0.674,P < 0.001;r=-0.602,P < 0.001, respectively).ConclusionsThe patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological me-chanism. Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.BACKGROUNDLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.The study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.METHODSThe study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.As an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels (15.1 ± 3.9 µmol/L vs. 11.5 ± 3.2 µmol/L, P = 0.02). Aortic distensibility was significantly lower in the patients with PD when compared to controls (4.8 ± 1.5 dyn/cm(2) vs. 6.2 ± 1.9 dyn/cm(2), P = 0.016). Additionally, the patients with PD had higher aortic strain and aortic stiffness index (13.4% ± 6.4% vs. 7.4% ± 3.6%, P < 0.001 and 7.3 ± 1.5 vs. 4.9 ± 1.9, P < 0.001 respectively). Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine (r = 0.674, P < 0.001; r = -0.602, P < 0.001, respectively).RESULTSAs an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels (15.1 ± 3.9 µmol/L vs. 11.5 ± 3.2 µmol/L, P = 0.02). Aortic distensibility was significantly lower in the patients with PD when compared to controls (4.8 ± 1.5 dyn/cm(2) vs. 6.2 ± 1.9 dyn/cm(2), P = 0.016). Additionally, the patients with PD had higher aortic strain and aortic stiffness index (13.4% ± 6.4% vs. 7.4% ± 3.6%, P < 0.001 and 7.3 ± 1.5 vs. 4.9 ± 1.9, P < 0.001 respectively). Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine (r = 0.674, P < 0.001; r = -0.602, P < 0.001, respectively).The patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological mechanism.CONCLUSIONSThe patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological mechanism. |
| Author | Zeki Yuksel Giinaydln Fahriye Feriha Ozer Ahmet Karagoz Osman Bektas Mehmet Baran Karatas Ash Vural Adil Bayramoglu Abdullah Celik Mehmet Yaman |
| AuthorAffiliation | Department of Cardiology, 0rdu University Medical School, 0rdu, Turkey Department of Neurology, 0rdu University Medical School, 0rdu, Turkey Department of Cardiology, Giresun University Medical School, Giresun, Turkey Department of Cardiology, Siyami Ersek Research and Training Hospital,？stanbul, Turkey |
| AuthorAffiliation_xml | – name: Department of Cardiology, 0rdu University Medical School, 0rdu, Turkey%Department of Neurology, 0rdu University Medical School, 0rdu, Turkey%Department of Cardiology, Giresun University Medical School, Giresun, Turkey%Department of Cardiology, Siyami Ersek Research and Training Hospital,?stanbul, Turkey – name: 2 Department of Neurology, Ordu University Medical School, Ordu, Turkey – name: 3 Department of Cardiology, Giresun University Medical School, Giresun, Turkey – name: 4 Department of Cardiology, Siyami Ersek Research and Training Hospital, İstanbul, Turkey – name: 1 Department of Cardiology, Ordu University Medical School, Ordu, Turkey |
| Author_xml | – sequence: 1 givenname: Zeki Yüksel surname: Günaydın fullname: Günaydın, Zeki Yüksel organization: Department of Cardiology, Ordu University Medical School, Ordu, Turkey – sequence: 2 givenname: Fahriye Feriha surname: Özer fullname: Özer, Fahriye Feriha organization: Department of Neurology, Ordu University Medical School, Ordu, Turkey – sequence: 3 givenname: Ahmet surname: Karagöz fullname: Karagöz, Ahmet organization: Department of Cardiology, Giresun University Medical School, Giresun, Turkey – sequence: 4 givenname: Osman surname: Bektaş fullname: Bektaş, Osman organization: Department of Cardiology, Ordu University Medical School, Ordu, Turkey – sequence: 5 givenname: Mehmet Baran surname: Karataş fullname: Karataş, Mehmet Baran organization: Department of Cardiology, Siyami Ersek Research and Training Hospital, İstanbul, Turkey – sequence: 6 givenname: Aslı surname: Vural fullname: Vural, Aslı organization: Department of Cardiology, Giresun University Medical School, Giresun, Turkey – sequence: 7 givenname: Adil surname: Bayramoğlu fullname: Bayramoğlu, Adil organization: Department of Cardiology, Ordu University Medical School, Ordu, Turkey – sequence: 8 givenname: Abdullah surname: Çelik fullname: Çelik, Abdullah organization: Department of Cardiology, Giresun University Medical School, Giresun, Turkey – sequence: 9 givenname: Mehmet surname: Yaman fullname: Yaman, Mehmet organization: Department of Cardiology, Ordu University Medical School, Ordu, Turkey |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26918017$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkV9LHDEUxfNg8f9XkFAoCLJjMskkmZdCEauCoA_2sYS7SWY362yyJjOr3U9vZFUsBAK5v3vO4eQA7YQYHEI_KKkobUl7vqh8zqGiQtJJwymtakJFRWhFCNtB-5_ve-gg5wUhjWp4vYv2atFSRajcR38v19CPMPgYcOywgWR9XEM2Yw8JJ58fsQ94VQAXhoyf_TDH95Aefchlw_rsIDs8BusS7t062rgCPCQHw7IsHKFvHfTZHb_fh-jP78uHi-vJ7d3VzcWv24lhdTtMrJWEMdLVRBBplOgUa7hj3ChrKEwZA7BGtdK20LS8Ya4cKjs3FQI4N5Idop9b3dU4XTprinWCXq-SX0L6pyN4_f8k-LmexbXmsmGlsiJwthV4htBBmOlFHFMokXUfXjbTl81Gu7duCSWUF_r03S7Fp9HlQS99Nq7vIbg4Zk2lUI1gSr0lO_ma7DPSxw8U4PsWMPMYZk--eH8wQiimala6eQVcupnB |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. Institute of Geriatric Cardiology 2015 |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: Institute of Geriatric Cardiology 2015 |
| DBID | 2RA 92L CQIGP W91 ~WA NPM 7X8 2B. 4A8 92I 93N PSX TCJ 5PM |
| DOI | 10.11909/j.issn.1671-5411.2016.01.003 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment |
| EndPage | 80 |
| ExternalDocumentID | PMC4753016 lnxzbxzz_e201601014 26918017 668382370 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: The authors declare that there is no conflict of interests regarding the publication of this paper |
| GroupedDBID | --- -05 -0E -S~ 2B. 2C~ 2RA 53G 5VR 92F 92I 92L 92M 93N 93R 9D9 9DE ABKZE ACGFS ADRAZ AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CAJEE CAJUS CCEZO CHBEP CIEJG CQIGP CW9 DIK EIHBH FA0 HYE JUIAU KQ8 M48 OK1 P2P Q-- Q-4 R-E RNS RPM RT5 S.. T8U TCJ TGQ U1F U1G U5E U5O W91 WFFXF ~N- ~WA -SE NPM 7X8 4A8 PSX 5PM |
| ID | FETCH-LOGICAL-c329t-dd70330f20607c86f8354e34c8dc1ab33aadc897d9a59453e53e17feb66a44c73 |
| IEDL.DBID | M48 |
| ISSN | 1671-5411 |
| IngestDate | Thu Aug 21 18:31:40 EDT 2025 Thu May 29 03:58:16 EDT 2025 Fri Sep 05 07:08:56 EDT 2025 Mon Jul 21 06:02:24 EDT 2025 Wed Feb 14 10:19:45 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Parkinson disease Homocysteine Aortic distensibility Aortic stiffness Cardiovascular risk |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c329t-dd70330f20607c86f8354e34c8dc1ab33aadc897d9a59453e53e17feb66a44c73 |
| Notes | BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease （PD）. Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased risk for future cardiovascular events. The objective of this study is to evaluate cardiovascular risk in patients with PD under levodopa treatment.MethodsThe study population consisted of 65 patients with idiopathic PD under L-dopa treatment. The control group included 32 age and gender matched individuals who had no cognitive decline. Echocardiographic measurements, serum homocysteine levels and elastic parameters of the aorta were compared between the patients with PD and controls.ResultsAs an expected feature of L-dopa therapy, the Parkinson group had significantly higher homocystein levels （15.1 ± 3.9 μmol/Lvs. 11.5 ± 3.2 μmol/L,P = 0.02）. Aortic distensibility was significantly lower in the patients with PD when compared to controls （4.8 ± 1.5 dyn/cm2vs. 6.2 ± 1.9 dyn/cm2,P = 0.016）. Additionally, the patients with PD had higher aortic strain and aortic stiffness index （13.4% ± 6.4%vs. 7.4% ± 3.6%,P 〈 0.001 and 7.3 ± 1.5vs. 4.9 ± 1.9,P〈 0.001 respectively）. Furthermore, serum homocysteine levels were found to be positively correlated with aortic stiffness index and there was a negative correlation between aortic distensibility and levels of serum homocysteine （r = 0.674,P 〈 0.001;r=-0.602,P 〈 0.001, respectively）.ConclusionsThe patients with PD under L-dopa treatment have increased aortic stiffness and impaired diastolic function compared to healthy individuals. Elevated serum homocysteine levels may be a possible pathophysiological me-chanism. Aortic distensibility; Aortic stiffness; Cardiovascular risk; Homocysteine; Parkinson disease 11-5329/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.11909/j.issn.1671-5411.2016.01.003 |
| PMID | 26918017 |
| PQID | 1768563887 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4753016 wanfang_journals_lnxzbxzz_e201601014 proquest_miscellaneous_1768563887 pubmed_primary_26918017 chongqing_primary_668382370 |
| PublicationCentury | 2000 |
| PublicationDate | 2016 2016-Jan 20160101 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – year: 2016 text: 2016 |
| PublicationDecade | 2010 |
| PublicationPlace | China |
| PublicationPlace_xml | – name: China |
| PublicationTitle | Journal of geriatric cardiology : JGC |
| PublicationTitleAlternate | Journal of Geriatric Cardiology |
| PublicationYear | 2016 |
| Publisher | Department of Cardiology, 0rdu University Medical School, 0rdu, Turkey%Department of Neurology, 0rdu University Medical School, 0rdu, Turkey%Department of Cardiology, Giresun University Medical School, Giresun, Turkey%Department of Cardiology, Siyami Ersek Research and Training Hospital,?stanbul, Turkey Science Press |
| Publisher_xml | – name: Department of Cardiology, 0rdu University Medical School, 0rdu, Turkey%Department of Neurology, 0rdu University Medical School, 0rdu, Turkey%Department of Cardiology, Giresun University Medical School, Giresun, Turkey%Department of Cardiology, Siyami Ersek Research and Training Hospital,?stanbul, Turkey – name: Science Press |
| References | 15539615 - Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):29-38 24780207 - J Am Heart Assoc. 2014 Apr 29;3(3):e000789 2405297 - Neurology. 1990 Feb;40(2):340-5 15365141 - Neurology. 2004 Sep 14;63(5):886-91 23434109 - Nutrition. 2013 Jun;29(6):876-80 24748879 - J Geriatr Cardiol. 2014 Mar;11(1):32-8 17225194 - Swiss Med Wkly. 2006 Dec 2;136(47-48):745-56 24402301 - Curr Atheroscler Rep. 2014 Feb;16(2):387 25561878 - Saudi J Biol Sci. 2015 Jan;22(1):19-23 23786433 - Clin Exp Hypertens. 2014;36(3):181-6 24175072 - JRSM Cardiovasc Dis. 2012 Sep 30;1(6):null 22123498 - Pharmacol Res. 2012 Mar;65(3):358-64 25577237 - Nutr J. 2015 Jan 10;14:6 17622392 - Can J Cardiol. 2007 Jul;23(9):707-10 12815652 - Mov Disord. 2003 Jul;18(7):738-50 11877368 - Circulation. 2002 Mar 5;105(9):1135-43 20029636 - Cardiovasc Psychiatry Neurol. 2009;2009:969752 6067254 - Neurology. 1967 May;17(5):427-42 24547918 - Expert Opin Drug Saf. 2014 Mar;13(3):351-60 9134272 - Clin Cardiol. 1997 May;20(5):426-32 24863078 - Herz. 2015 Jun;40(4):679-84 18036161 - J Intern Med. 2008 Jan;263(1):90-8 23996286 - Eur Heart J. 2013 Oct;34(38):2949-3003 24338546 - Cardiol J. 2013;20(6):665-71 12666094 - Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5 12645638 - Am J Cardiol. 2003 Feb 6;91(3A):7A-11A 17416288 - Arch Med Res. 2007 May;38(4):411-6 7897409 - J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):293-9 18490274 - Eur J Echocardiogr. 2008 Nov;9(6):803-8 24609213 - J Hypertens. 2014 Apr;32(4):744-5 25241219 - Arch Cardiovasc Dis. 2014 Dec;107(12):654-63 12533089 - Arch Neurol. 2003 Jan;60(1):59-64 17000623 - Eur Heart J. 2006 Nov;27(21):2588-605 25819857 - Am Heart J. 2015 Apr;169(4):508-14 |
| References_xml | – reference: 23786433 - Clin Exp Hypertens. 2014;36(3):181-6 – reference: 24338546 - Cardiol J. 2013;20(6):665-71 – reference: 23996286 - Eur Heart J. 2013 Oct;34(38):2949-3003 – reference: 24780207 - J Am Heart Assoc. 2014 Apr 29;3(3):e000789 – reference: 15539615 - Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):29-38 – reference: 17622392 - Can J Cardiol. 2007 Jul;23(9):707-10 – reference: 17225194 - Swiss Med Wkly. 2006 Dec 2;136(47-48):745-56 – reference: 12533089 - Arch Neurol. 2003 Jan;60(1):59-64 – reference: 25561878 - Saudi J Biol Sci. 2015 Jan;22(1):19-23 – reference: 18490274 - Eur J Echocardiogr. 2008 Nov;9(6):803-8 – reference: 24609213 - J Hypertens. 2014 Apr;32(4):744-5 – reference: 12666094 - Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5 – reference: 15365141 - Neurology. 2004 Sep 14;63(5):886-91 – reference: 25241219 - Arch Cardiovasc Dis. 2014 Dec;107(12):654-63 – reference: 12645638 - Am J Cardiol. 2003 Feb 6;91(3A):7A-11A – reference: 12815652 - Mov Disord. 2003 Jul;18(7):738-50 – reference: 22123498 - Pharmacol Res. 2012 Mar;65(3):358-64 – reference: 20029636 - Cardiovasc Psychiatry Neurol. 2009;2009:969752 – reference: 24402301 - Curr Atheroscler Rep. 2014 Feb;16(2):387 – reference: 25819857 - Am Heart J. 2015 Apr;169(4):508-14 – reference: 11877368 - Circulation. 2002 Mar 5;105(9):1135-43 – reference: 24175072 - JRSM Cardiovasc Dis. 2012 Sep 30;1(6):null – reference: 17000623 - Eur Heart J. 2006 Nov;27(21):2588-605 – reference: 23434109 - Nutrition. 2013 Jun;29(6):876-80 – reference: 24748879 - J Geriatr Cardiol. 2014 Mar;11(1):32-8 – reference: 25577237 - Nutr J. 2015 Jan 10;14:6 – reference: 18036161 - J Intern Med. 2008 Jan;263(1):90-8 – reference: 9134272 - Clin Cardiol. 1997 May;20(5):426-32 – reference: 2405297 - Neurology. 1990 Feb;40(2):340-5 – reference: 24547918 - Expert Opin Drug Saf. 2014 Mar;13(3):351-60 – reference: 24863078 - Herz. 2015 Jun;40(4):679-84 – reference: 7897409 - J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):293-9 – reference: 6067254 - Neurology. 1967 May;17(5):427-42 – reference: 17416288 - Arch Med Res. 2007 May;38(4):411-6 |
| SSID | ssj0058542 |
| Score | 2.1312609 |
| Snippet | BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease （PD）. Since L-dopa treatment was shown to increase serum... Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine... BackgroundLevodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum... |
| SourceID | pubmedcentral wanfang proquest pubmed chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 75 |
| Title | Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment |
| URI | http://lib.cqvip.com/qk/88644X/201601/668382370.html https://www.ncbi.nlm.nih.gov/pubmed/26918017 https://www.proquest.com/docview/1768563887 https://d.wanfangdata.com.cn/periodical/lnxzbxzz-e201601014 https://pubmed.ncbi.nlm.nih.gov/PMC4753016 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1RSxwxEB5EqfRFbGvbU1tS0Me1m0022TyISFGkcH3qgS9lSbJZtRw5vTv1vF_vzN7e0qNSCvuWzbJMJplvMjPfABwUmeWZ9UXinK8S6ZxLLALlRBgnFMKFWtdUjdz_oS4G8vtlfrkGyyT2VoCTF1076ic1GA-PZndPJ7jhj5sNb1Lz9XezYY640jzJJSe3j6uGjZN4QDfQSCnyy_qyCzAgSG766nRTNuHwvz5HFAzXo3h1h4blJVD6d27lq0cbaxuv_jBb59uw1eJNdrpQkDewFuJb2Oy3EfV38Ouso_tmo5r5lfRURonn7Cayln11wujallGldFM0xtrwDqNKtDEbhgd0cm8t67LXd2Bwfvbz20XStlxIvMjMNKkqPAFEWmepSrUvVE33QkFIX1SeWyeEtZUvjK6MzY3MRcCH6zo4payUXov3sB5HMXwE5qwlkkMn0cFDTJa5CqESReE4UQBK04O9TpLl7YJao1SqoMCkTnvwZSnbEhWeohg2htH9pOToIOV4ahS6Bx8Wsu6mZ8pwNLk4oldWoXuByLRXR-LNdUOqLdFvw2XuwUG7XuVSF8thnM3dbD4vAylC0914958_vwev6c3FTc0-rE_H9-ETYpep-9xo4TMlR-uL |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+cardiovascular+risk+in+patients+with+Parkinson+disease+under+levodopa+treatment&rft.jtitle=%E8%80%81%E5%B9%B4%E5%BF%83%E8%84%8F%E7%97%85%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Zeki+Yuksel+Giinaydln+Fahriye+Feriha+Ozer+Ahmet+Karagoz+Osman+Bektas+Mehmet+Baran+Karatas+Ash+Vural+Adil+Bayramoglu+Abdullah+Celik+Mehmet+Yaman&rft.date=2016&rft.issn=1671-5411&rft.volume=13&rft.issue=1&rft.spage=75&rft.epage=80&rft_id=info:doi/10.11909%2Fj.issn.1671-5411.2016.01.003&rft.externalDocID=668382370 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F88644X%2F88644X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Flnxzbxzz-e%2Flnxzbxzz-e.jpg |